![](https://news.europawire.eu/wp-content/uploads/2013/12/novartis.jpg)
Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an incurable cancer of the plasma cells, a type of white blood cell … Read the full press release